The Petri Dish: FDA delays Sarepta decision; Novartis buys Avrobio drug

The FDA has given itself a few more weeks to decide on the fate of Sarepta Therapeutics' latest treatment for Duchenne muscular dystrophy.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 25, 2023 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news